Unicycive Posts $7.0M Q3 Loss, $59M Cash Through 2027 OLC PDUFA
UNCY is trading near its 52-week low of $3.33 (6.0% above the low).
Summary
Unicycive reported a $7.0 million Q3 loss and $59 million in cash that it says lasts beyond 2027, past the March 25, 2027 OLC PDUFA date. The new detail is CMS's $12.85 per-treatment binder funding starting January 2027, which the company says could pair with TDAPA reimbursement if OLC is approved.
Key Events · Earnings and Guidance · UNCY
-
Q3 Loss Widens on Launch Spend
Net loss was $(7.0) million, or $(0.25) per share, versus $(6.0) million, or $(0.33) per share, a year earlier. G&A rose to $6.6 million from $4.4 million, including $1.4 million of commercial launch preparation, while R&D fell to $2.2 million from $3.0 million.
-
$59M Cash Covers PDUFA and Launch
Cash, cash equivalents and marketable securities were approximately $59 million at September 30, 2026, with expected runway beyond 2027, including anticipated launch expenses for OLC if approved.
-
CMS Adds $12.85 Per-Treatment Binder Funding
The October 28, 2026 CY2027 ESRD PPS final rule establishes permanent phosphate binder funding in the dialysis bundle through a $12.85 per-treatment addition to the base rate effective January 1, 2027, plus a hyperphosphatemia quality measure starting payment year 2029.
-
TDAPA Path Still Rests With FDA and CMS
Unicycive believes OLC qualifies for TDAPA and could get two years of separate reimbursement at 100% of average sales price, but NDA classification and TDAPA eligibility are agency determinations made at approval.
Analysis · UNCY · Life Sciences
Cash, not the loss, is the quarter's headline: $59 million as of September 30 funds operations beyond 2027, covering the March 25, 2027 PDUFA date for oxylanthanum carbonate and even a launch if approved. Spending is shifting toward commercialization, with G&A rising to $6.6 million from $4.4 million, including $1.4 million tied to launch preparation, while R&D fell to $2.2 million from $3.0 million. Note that the $1.8 million of other income is a non-cash mark-to-market gain on the warrant liability, not cash generated. The genuinely new commercial datapoint is CMS's October 28 final rule adding $12.85 per treatment for phosphate binders to the dialysis base rate from January 1, 2027; if OLC also wins TDAPA, the company argues providers would get two years of separate 100% ASP reimbursement on top. Both the FDA classification call and TDAPA eligibility remain with the agencies, so the economics hinge on decisions outside the company's control.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UNCY was trading at $3.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.9M. The 52-week trading range was $3.33 to $8.74. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.